Patient P-01578
Therapy response
Unstable
Tolerance
Favorable
GI state
Improving
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
14%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S19
- Day 26 Trajectory diverged from prediction — Observed response fell below the model's expected path.
What changed?
Trajectory began diverging from predicted response on Day 26.
Primary contributors, last 14 days
- GI instability-8
- Inflammatory activity-3
- Nutritional resilience+3
What helped?
No interventions yet.
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion20/100
worsening · +10.0 vs previous 14 d
Toxicity
Blood14.4/100
worsening · +2.0 vs previous 14 d
Sleep quality
Wearable36.9/100
stable · -1.6 vs previous 14 d
Energy level
Daily log5.8/10
worsening · -0.5 vs previous 14 d
Stress level
Daily log5/10
worsening · +0.6 vs previous 14 d
Steps
Wearable8,325
worsening · -579 vs previous 14 d
Adherence
Companion89.8 %
stable · +3.1 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 68 from the failing basin, 42 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
Main detractors to watch
- FUT2 non-secretorhidden · steering -10.6
- Rapid metabolizerhidden · steering -8
- Histamine loadperturbation · steering -7.8
- Antibiotic courseperturbation · steering -4.7
- Histamine loaddetractor · GI +4.3 next day
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Histamine load+4.3detractor · 95%
- Alcohol+1.4no signal · 35%
- Dietary fat load-0.9no signal · 29%
- Spicy / capsaicin+0.6no signal · 16%
- Simple carbohydrates+0.3no signal · 15%
- Insoluble fibre+0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- MicrobiomeAkkermansia low → thinner mucus layer
- Autonomic recovery ↓20
- WearableShort sleep window
DNA
Fictional pharmacogenomic panel
- FUT2 rs601338 AA (non-secretor)Reduced mucosal fucosylation
- CYP2D6 Rapid metabolizerExpected exposure
Microbiome
Shannon diversity 4.5 · butyrate capacity 82/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumNormal
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 41 ms
- Sleep
- 6.8 h
- Steps
- 7,587
- Resting HR
- 69 bpm
Daily log: GI score 20, nutritional resilience 60, adherence 90.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Protect a 7.5-hour sleep window; screens off 30 minutes before
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01773 | 48% | S05 | AD-05 | improved | 27 |
| P-01483 | 33% | S14 | AD-05 | no change | 35 |
| P-01679 | 32% | S12 | AD-05 | no change | 39 |
| P-01377 | 31% | S11 | AD-05 | no change | 42 |
| P-01541 | 30% | S09 | AD-05 | no change | 43 |
| P-01848 | 29% | S05 | AD-05 | no change | 23 |
| P-01804 | 27% | S19 | AD-05 | improved | 61 |
| P-01313 | 34% | S01 | BR-03 | improved | 32 |
| P-01350 | 32% | S19 | BR-03 | no change | 34 |
| P-01450 | 30% | S09 | BR-03 | no change | 36 |
| P-01468 | 28% | S06 | BR-03 | no change | 41 |
| P-01689 | 26% | S13 | BR-03 | no change | 50 |